Viewpoints 

Q: What is Dr.Evidence's core offering?

A: As CTO of Dr.Evidence, I'm proud to say we've built the most contemporary, comprehensive and AI-enabled landscape intelligence platform for life sciences. It’s really a force multiplier for our clients, helping them exponentially increase quality and speed in the regulatory submission and commercialization process. Our flagship product, Label Intelligence, has earned its position as the market leader through years of innovation and refinement. Flanked by Regulatory Intelligence and Literature Search modules, with Trials Intelligence launching in Q1 2025, these components work together as an integrated ecosystem, specifically engineered for life sciences workflows.

Q: What distinguishes Dr.Evidence from competitors in the market?

A: I'll be direct: we created this category, and we continue to define it. We're already executing our next generation of innovations. Our twenty years of experience has helped us build unmatched relationships across the life sciences sector, which informs every technical decision we make. This isn't just about longevity – it's about deep domain expertise that's woven into our technology stack. I take particular pride in the fact that our ten largest clients have stayed with us for over a decade. In our industry, that kind of retention only happens when you consistently deliver technical excellence.

Q: What are Dr.Evidence’s core competencies?

A: Let me share what we've mastered through years of focused development. We've built sophisticated systems for rapid data extraction and aggregation that handle the complexity of life sciences data at scale. Our AI development capabilities are particularly advanced – we're not implementing generic solutions but creating specialized models for life science applications. We've honed time-tested rapid deployment methodologies while maintaining the deep domain expertise that makes our solutions truly valuable. These aren't just competencies we claim; they're capabilities we demonstrate daily across our client base.

Q: Why should companies choose Dr.Evidence over building internal solutions?

A: Having overseen a significant number of technical implementations, I can tell you that building these capabilities internally is a massive undertaking. Life sciences companies typically spend well over $1M annually just on personnel, before considering infrastructure and support costs. But more importantly, why reinvent what we've spent decades perfecting? We've already solved the complex challenges of software engineering, DevOps, infrastructure management, and enterprise architecture in the life sciences context. Our platform lets clients focus on their core business while leveraging our technical expertise and infrastructure.

Q: What new capabilities are you introducing?

A: I'm particularly excited about our upcoming releases. Our Trials Intelligence module, launching in Q1 2025, brings sophisticated visualization capabilities to clinical trial analysis. Even more transformative is our proprietary Generative AI large language model, also coming  in Q1. What makes these releases special is how we're integrating them into our existing platform – they're not bolt-on solutions but integral parts of our ecosystem.

Q: How does Dr.Evidence's AI approach differ from competitors?

A: We've developed over 25 specialized AI models specifically for life sciences applications. This gives us complete control over our AI stack – we can curate and adjust these models as needed without external dependencies. Our approach to generative AI is particularly sophisticated. We've designed our system to eliminate IP leakage risks by maintaining full control over what goes into and comes out of our large language models. This level of security and control is non-negotiable in our industry, and we've built it into our core architecture.

Q: What ROI can clients expect?

A: From our extensive client data, we deliver multiple paths to ROI. Clients generate dramatic efficiencies in their path to market.   They gain immediate access to our enterprise-grade infrastructure without capital investment. Our SaaS delivery model enables rapid deployment and scaling. But perhaps most importantly, they get proven, hardened solutions for critical workflows like labeling and regulatory intelligence – areas where efficiency is crucial, and technical failures can have serious consequences.

Q: Who is an ideal customer for Dr.Evidence?

A: Our platform's architecture allows it to scale effectively from emerging biotech firms to multinational pharmaceutical corporations. We've designed it this way deliberately, understanding that life sciences companies of all sizes face similar challenges but at different scales. Our ideal customers are organizations that want to focus their technical resources on core competencies while leveraging our platform for critical workflows. We're particularly valuable for companies that need to optimize their operational efficiency to get their products to market and keep them there.

Q: What makes Dr.Evidence’s platform approach unique?

A: From an architectural standpoint, we've taken a fundamentally different approach. Instead of offering disconnected tools, we've built an integrated system where each component enhances the others. Our scientific content isn't just a database – it's deeply integrated with our platform's functionality, creating a seamless experience across different workflows. This architectural approach means that whether you're working in clinical development, labeling, regulatory, PV/safety or medical affairs, you're leveraging the same robust infrastructure and consistent data model. It's an approach that could only come from our deep understanding of both the technical and domain challenges in life sciences.